The US obtained access to doses that it will donate to low- and low-middle-income countries, Merck & Co. is lining up government purchases of its Phase III drug, and Ocugen will submit a BLA in the US rather than pursue an EUA for Bharat's vaccine. Plus progress and setbacks for COVID-19 therapeutics. 

News and views from day one of the BIO Digital annual meeting include debate about when FDA will go back to the offices, industry's role in pandemic-related policy discussions and how to prepare for the next pandemic. 

News and views from day one of the BIO Digital annual meeting include debate about when FDA will go back to the offices, industry's role in pandemic-related policy discussions and how to prepare for the next pandemic. 

MSD India outlines further specifics around the just-announced voluntary licensing deal for molnupiravir with Indian firms, noting an expectation to discuss local data needs with the country’s regulator. All eyes are also on whether non-licensee Natco will stay the course for its application for the investigational antiviral.